TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Buy” by Brokerages

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) have been given a consensus recommendation of “Buy” by the eleven analysts that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $174.30.

A number of equities analysts have recently weighed in on the stock. Stephens lifted their price target on shares of TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Piper Sandler reissued an “overweight” rating and issued a $180.00 target price on shares of TransMedics Group in a research note on Monday, October 7th. Baird R W upgraded TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Robert W. Baird started coverage on TransMedics Group in a report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective on the stock. Finally, Morgan Stanley increased their target price on TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th.

Insider Activity

In related news, Director James R. Tobin sold 20,000 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $159.33, for a total transaction of $3,186,600.00. Following the completion of the transaction, the director now owns 173,146 shares in the company, valued at approximately $27,587,352.18. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the sale, the director now owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Waleed H. Hassanein sold 8,625 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $153.42, for a total value of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at approximately $9,457,269.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 55,580 shares of company stock worth $8,837,283 over the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of TransMedics Group by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after acquiring an additional 23,979 shares during the period. Driehaus Capital Management LLC grew its holdings in TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares during the period. First Light Asset Management LLC grew its holdings in TransMedics Group by 22.0% during the fourth quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after purchasing an additional 136,217 shares during the period. Allspring Global Investments Holdings LLC increased its position in TransMedics Group by 3.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 730,010 shares of the company’s stock worth $53,977,000 after buying an additional 21,737 shares during the last quarter. Finally, Wasatch Advisors LP acquired a new stake in shares of TransMedics Group in the first quarter valued at approximately $32,162,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Trading Down 1.4 %

NASDAQ:TMDX opened at $129.97 on Thursday. The company has a current ratio of 9.37, a quick ratio of 8.48 and a debt-to-equity ratio of 2.67. TransMedics Group has a 1-year low of $36.42 and a 1-year high of $177.37. The firm has a market capitalization of $4.34 billion, a price-to-earnings ratio of 3,249.25 and a beta of 1.99. The business’s 50-day moving average price is $154.12 and its two-hundred day moving average price is $137.55.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.14. The business had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a net margin of 0.84% and a return on equity of 15.98%. TransMedics Group’s revenue for the quarter was up 117.7% on a year-over-year basis. During the same period last year, the company posted ($0.03) EPS. On average, equities analysts expect that TransMedics Group will post 1.22 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.